D-cycloserine/lurasidone (NRX-101)

Small molecule

Phase 3topline reported

Evidence outlook · registrational

Bipolar Depression: topline reported 2024-04-30

Its supporting mid-stage studies have completed. The sponsor reported topline results on 2024-04-30 (NRX-101 vs lurasidone Phase 2b/3 (NCT03395392) missed its primary endpoint). The announcement is listed under Regulatory events.

Also in development:Major Depressive Disorder · Phase 2/3

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Bipolar Depression
Phase 2/3 (3)
Bipolar Depression
NCT03395392 · NeuroRx, Inc.
2022-05-12 – 2024-03-30 · Bipolar Depression, Suicidal Ideation and Behavior
What this study did
NCT03402152 · NeuroRx, Inc.
2018-11-01 – 2021-06-01 · Bipolar Depression, Suicidal Ideation
What this study did
Major Depressive Disorder
Phase 2 (2)
Bipolar Depression
NCT02974010 · NeuroRx, Inc.
2018-01-15 – 2019-11-20 · Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
What this study did
Other / comorbidity
NCT06128213 · NeuroRx, Inc.
2024-03-31 – 2024-09-30 · Urinary Tract Infections, Pyelonephritis
What this study did
Phase 1 (1)
Major Depressive Disorder
NCT07785102 · Mclean Hospital
2026-10-01 – 2027-03-31 · Major Depression
What this study did

Competitive landscape

This drug's own stage for Bipolar Depression: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
D-Cycloserine / Lurasidone (NRX-101): this drugPhase 3Small moleculeNMDA receptor (glycine site) + dopamine/5-HT receptornot yet gradedNo reviewed efficacy summary in this indication
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Lumateperone (Caplyta)ApprovedSmall moleculeSerotonin 5-HT2A / dopamine D1-D2 receptornot yet gradedNo reviewed efficacy summary in this indication
LurasidoneApprovedSmall moleculeDopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
ABBV-932
Phase 1(overall)
Small moleculeDopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow D-cycloserine/lurasidone (NRX-101) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1Major Depressive DisorderRecruiting
Est. primary completion 2026-12-31 · NCT07785102 · CT.gov ↗
What to watch
2027 (1)
December 2027 (1)
Phase 2/3Major Depressive DisorderRecruiting
Est. primary completion 2027-12-31 · NCT07227103 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 April 2024Topline resultNRX-101 vs lurasidone Phase 2b/3 (NCT03395392) missed its primary endpoint
NRx Pharmaceuticals, Inc. · Source ↗